Defective RB1 does not bind E2F1,(E2F2,E2F3)

Stable Identifier
R-HSA-9659782
Type
Reaction [transition]
Species
Homo sapiens
Compartment
nucleoplasm
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Defective RB1 does not bind E2F1,(E2F2,E2F3)
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Low penetrance germline RB1 mutants RB1 N480del and RB1 R661W, reported in retinoblastoma, localize to the nucleus but have >95% reduced binding to E2F1. These two mutations lie in the pocket region of RB1, N480del in the pocket domain A (amino acid residues 373 579) and R661W in the pocket domain B (amino acid residues 640 771). Binding of RB1 N480del and RB1 R661W to E2F2 and E2F3 has not been tested but is assumed to be affected like E2F1 binding (Otterson et al. 1997). RB1 T738_R775del mutant (also known as RB1 delEx22) is a cancer mutant that is generated by an in-frame deletion or by a splice site mutation, which both result in a mutant protein that lacks the amino acid sequence encoded by exon 22 of the RB1 gene. This mutant lacks a part of the pocket domain B and is unable to bind to the adenoviral oncoprotein E1A (Templeton et al. 1991). RB1 T738_R775del is not able to inhibit E2F1-mediate transcriptional transactivation (Helin et al. 1993) and is unable to bind to E2Fs (Ji et al. 2004).
RB1 R661Q mutant has been reported in cancer and is predicted to be pathogenic, but has not been functionally tested; it is annotated as a candidate based on its similarity with RB1 R661W.
RB1 C706F mutant, reported in lung and breast cancer, maps to the pocket domain B and shows a complete loss of binding to E2F1 (Otterson et al. 1997). Based on its similarity with RB1 C706F, RB1 C706Y mutant, reported in lung cancer, has been annotated as a candidate.
Another in-frame deletion mutant of RB1, RB1 I703_E737del (also known as RB1 delEx21) has been reported in several different cancer types. This mutant is generated by an in-frame deletion of exon 21 and is assumed to have impaired binding to E2Fs, due to its partially deleted pocket domain B. RB1 I703_E737del is annotated as a candidate for impaired binding to E2F1, E2F2 and E2F3.
Literature References
PubMed ID Title Journal Year
9342358 Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function

Kaye, FJ, Otterson, GA, Chen, Wd, Coxon, AB, Khleif, SN

Proc. Natl. Acad. Sci. U.S.A. 1997
15469821 An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant

Ji, P, Rekhtman, K, Pagano, M, Bloom, J, Jiang, H, Zhu, L, Ichetovkin, M

Mol. Cell 2004
8413249 Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein

Fattaey, A, Harlow, E, Helin, K

Mol. Cell. Biol. 1993
1826560 Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering

Park, SH, Weinberg, RA, Lanier, L, Templeton, DJ

Proc. Natl. Acad. Sci. U.S.A. 1991
Participants
Input
Participates
as an event of
This event is regulated
Negatively by
Regulator
Cyclin E:p-T160-CDK2 [nucleoplasm] (Homo sapiens)
Regulator
p-T172-CDK4,p-T177-CDK6:CCND:CDKN1A,CDKN1B,(CDKN1C); p-T172-CDK4,p-T177-CDK6:CCND; (p-T172-CDK4,p-T177-CDK6:CCND:p-Y88-CDKN1B) [nucleoplasm] (Homo sapiens)
Active Unit
p-T172-CDK4,p-T177-CDK6:CCND [nucleoplasm]
Normal reaction
RB1 binds and inhibits E2F1/2/3:DP1/2 complexes (Homo sapiens)
Functional status

Loss of function and partial loss of function of RB1 mutants (E2F binding) [nucleoplasm]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2020-05-07)
Reviewed
Dick, FA  (2020-05-17)
Created
Orlic-Milacic, M  (2019-09-05)
Cite Us!